New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
10:01 EDTIBM, ATLS, TWO, ALV, XEC, EXAS, XTEX, RSO, FFIV, XTXI, ABR, NYMT, ET, BIG, OSUROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arbor Realty (ABR) initiated with a Buy at Deutsche Bank... Big Lots (BIG) initiated with a Buy at Citigroup... Crosstex Energy LP (XTEX) initiated with an Outperform at Credit Suisse... Crosstex Energy (XTXI) initiated with an Outperform at Credit Suisse... Exact Sciences (EXAS) initiated with a Buy at Mizuho... ExactTarget (ET) initiated with a Buy at Roth Capital... F5 Networks (FFIV) initiated with an Outperform at FBR Capital... New York Mortgage (NYMT) initiated with a Buy at Deutsche Bank... OraSure (OSUR) initiated with a Buy at Mizuho... Resource Capital (RSO) initiated with a Hold at Deutsche Bank... Two Harbors (TWO) initiated with a Buy at Deutsche Bank... Cimarex Energy (XEC) initiated with a Buy at Global Hunter... IBM (IBM) initiated with a Buy at Topeka... Autoliv (ALV) initiated with a Neutral at Guggenheim... Atlas Energy (ATLS) initiated with an Overweight at Stephens.
News For ABR;XTEX;BIG;XTXI;EXAS;ET;FFIV;OSUR;NYMT;RSO;XEC;TWO;IBM;ALV;ATLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2015
09:55 EDTALVBofA/Merrill U.S. autos analysts hold an analyst/industry conference call
Subscribe for More Information
08:43 EDTIBMIBM estimates lowered at Credit Suisse ahead of the Q1 report
Credit Suisse lowered IBM estimates ahead of the Q1 report on April 20 and reiterated its Underperform rating and $125 price target on the stock. The firm's Q1 estimates for EPS and revenue go to $2.84/$19.8B versus consensus of $2.86/$19.9B and FY15 to $15.59/$85B versus consensus of $15.98/$85.4B. Credit Suisse concerns remain a weak order book and a reduction in industry-wide deal sizes, margin dilution from the cloud despite any revenue growth, less effective restructuring, and internal turmoil and underinvestment.
07:50 EDTXECCimarex Energy price target raised to $150 from $130 at Stifel
Subscribe for More Information
07:19 EDTALVDeutsche sees upside potential for Mobileye, raises target
After speaking with Dr. Mark Rosekind, the National Highway Traffic Safety Administration's new Administrator, Deutsche Bank believes the U.S. is about to adopt a more proactive stance on active safety technologies like Forward Crash Avoidance and Mitigation Systems. It thinks FCAM growth is likely to exceed its prior assumptions, providing upside potential for Mobileye (MBLY) and possibly Delphi Automotive (DLPH) and Autoliv (ALV). Deutsche raised its price target for Mobileye shares to $55 from $53 and keeps a Buy rating on the name.
07:15 EDTXECCimarex Energy downgraded to Neutral from Outperform at Macquarie
Macquarie downgraded Cimarex Energy to Neutral with a $115 price target due to valuation.
06:42 EDTXECCimarex Energy coverage resumed with a Neutral at Goldman
Target $125.
April 14, 2015
10:16 EDTBIGHigh option volume stocks
High option volume stocks: NSAM ALU CJES BIG CMRX ERIC NTAP TMO KN CIG
08:35 EDTATLSAtlas Energy and Atlas Resource Partners announce management changes
Subscribe for More Information
April 13, 2015
17:13 EDTIBMIBM Medtronic to partner to improve diabetes care
IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
17:12 EDTIBMIBM acquires Cleveland-based Explorys and Dallas-based Phytel
Subscribe for More Information
17:10 EDTIBMIBM establishes a Watson Health Cloud
Subscribe for More Information
08:01 EDTEXASExact Sciences says Cologuard receives coverage by several health plans in Q1
Since the start of 2015, several insurers began covering Cologuard as a noninvasive colon cancer screening test. In addition to several smaller regional providers, insurance plans covering the test now include: Anthem Blue Cross and Blue Shield, a leading national health plan with more than 37 million members across 14 states, Tufts Health Plan, with more than 1 million members across Massachusetts and Rhode Island and ranked the number one health plan for quality in the country for its Commercial plans and its Medicaid plans, CareFirst BlueCross BlueShield PPO, with 2.3 million eligible members across Maryland, District of Columbia and Northern Virginia, Excellus BCBS WNY, with more than 1.4 million members across Western New York and Dean Health Plan, insuring more than 272,037 members across Central Wisconsin.
April 8, 2015
12:21 EDTIBMIBM announces U.S. Army is using IBM Hybrid Cloud for logistics
Subscribe for More Information
11:08 EDTFFIVCybersecurity stocks in focus after White House security breach
Subscribe for More Information
10:01 EDTIBMIBM announces longstanding collaboration with Care.com
Subscribe for More Information
09:36 EDTFFIVSingtel acquires cybersecurity company Trustwave for $810M
Subscribe for More Information
07:53 EDTEXASExact Sciences survey results positive, says JMP Securities
After surveying 102 high-FIT/FOBT prescribing primary care and ob/gyn physicians who have been prescribing ColoGuard for at least four months, JMP Securities says that utilization of Exact Sciences' ColoGuard is increasing at a rapid pace. The firm adds that doctors are becoming more optimistic regarding the potential long-term penetration of ColoGuard into the market. The firm reiterates a $27 price target and Outperform rating on the shares.
April 7, 2015
16:55 EDTIBMXerox upgraded to Buy ahead of Q1 results at Citigroup
Subscribe for More Information
09:19 EDTIBMCLSA holds an analyst/industry conference call
Subscribe for More Information
06:31 EDTIBMIBM an unlikely target for activists, Reuters columnist says
Shareholders calling for activist investors to take aim at IBM are likely to be disappointed, according to a Reuters columnist. The company has already carried out a great deal of financial engineering, and it will probably need to spend heavily on R&D and invest in its business for a couple of years in order to turn itself around, the columnist believes. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use